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Background. An ectopic pregnancy can be a life-threatening condition. Early diagnosis with ultrasonography and quantitative beta-
human chorionic gonadotrophin (β-hCG) measurement has improved early and accurate diagnosis and treatment. Medical management 
with methotrexate internationally has a success rate of up to 93%, but there is a paucity of data on this treatment option in developing 
countries.
Objective. To determine the success of methotrexate treatment for ectopic pregnancies at a referral hospital in a developing country. This 
non-surgical, outpatient treatment seems a good option in hospitals with an ever-rising pressure on bed occupation and long waiting lists 
for emergency surgery.
Methods. A 5-year retrospective audit was performed on 124 patients treated for ectopic pregnancies with methotrexate at Tygerberg 
Hospital, Cape Town, South Africa.
Results. With success defined as a β-hCG level of <15 IU/L without requiring surgical intervention, the success rate was 44%. Fifteen 
per cent of medically managed patients required surgery. The remaining 41% were lost to follow-up. One patient had a major adverse 
outcome with a ruptured ectopic and required 2 units of blood, resuscitation and emergency laparotomy.
Conclusion. Medical management of ectopic pregnancies is a safe and effective management option, as proven by international data, 
but at Tygerberg Hospital the safety of this treatment modality cannot be guaranteed because of poor follow-up. Improvement in patient 
selection with consideration of predictors of success and thorough counselling, as well as full informed consent, is recommended before 
using this treatment modality. A new follow-up system should be developed at Tygerberg Hospital to guarantee patient safety.
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There has been a global increase in the incidence of 
ectopic pregnancies.[1] This potentially life-threatening 
condition is ranked among the top direct obstetric 
causes of maternal mortality in South Africa (SA). 
According to the Confidential Enquiry into Maternal 
Deaths,[2] 1.5% of maternal deaths were caused by ectopic pregnancy 
in the 2008 - 2010 triennium, which is an increase compared with the 
2005 - 2007 triennium. Continual improvement in ultrasonography 
and quantitative measurement of the beta-unit of human chorionic 
gonadotropin (β-hCG) have improved early and accurate diagnosis 
of ectopic pregnancies.[3] In carefully selected patients, medical 
management with methotrexate has shown a success rate of about 
90%.[4] Theoretically this non-surgical, potentially outpatient treatment 
modality seems a good solution in a hospital with ever-rising pressure 
on bed occupation and long waiting lists for emergency surgery.
In Europe and North America, the incidence of ectopic pregnan-
cies is 1 - 2% of all pregnancies.[5] Scanty data are available for SA. In 
1995, a study at Umtata Hospital, Transkei, quoted an incidence of 
11/1 000 reported pregnancies, with a mortality rate of 2%.[6]
The reason for tubal implantation in an ectopic pregnancy is 
unknown, but retention of the embryo as a result of impaired embryo-
tubal transport is a common theory. Causes of fallopian tube pathology 
include genital tract infection, tubal surgery, and a previous ectopic 
pregnancy.[7] Other risk factors include pelvic adhesions, conception 
from assisted reproductive technologies, a pregnancy with current use 
of an intrauterine contraceptive device, and cigarette smoking.[3]
The use of methotrexate for the medical treatment of ectopic 
pregnancies was first described in 1982.[8] Methotrexate is a folic 
acid antagonist that inhibits dihydrofolate reductase, which 
reduces folic acid to tetrahydrofolate, essential in the synthesis 
of DNA and RNA. Methotrexate inhibits growth in any rapidly 
dividing tissue such as trophoblasts and is excreted largely by the 
kidneys.[9] Side-effects associated with the use of methotrexate for 
ectopic pregnancies include abdominal pain, possibly caused by 
tubal abortion or tubal stretching, which usually responds to non-
steroidal anti-inflammatory treatment. Approximately half of 
ectopic masses will increase in size after methotrexate treatment, 
because of haematoma formation. An asymptomatic increase 
in size of the ectopic mass should therefore not be interpreted as 
treatment failure.[10] Methotrexate can be stored in the liver and 
kidneys, so a delay in conception for a period of at least 12 weeks is 
recommended.[1] Methotrexate may have a short negative effect on 
oocyte production, but this improves after 180 days.[11]
There are three main medical treatment regimens. The single-dose 
methotrexate regimen consists of a dose of 50 mg/m2 administered 
intramuscularly or intravenously. The β-hCG level is measured on 
post-treatment days 4 and 7. If there is a less than 15% decrease in the 
β-hCG level between these days, a second dose is given. The β-hCG is 
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then measured weekly until it reaches a non-
pregnant level.[7] The other regimens are the 
two-dose and fixed multidose regimens.
There are no randomised trials comparing 
the different treatment protocols. In a large 
meta-analysis comparing data from 26 trials 
and 1 327 cases, the success of the multidose 
regimen was 93% and that of the single-dose 
regimen 88%.[4] The average time to full 
resolution to a β-hCG level of <15 IU/L is 
35 days, but it can take up to 109 days, with 
20% of patients requiring more than one 
treatment cycle.[4] The longest time reported 
from initial treatment to tubal rupture was 
31 days.[4]
The cost of outpatient treatment v. surgery 
varies widely, but many cost analyses favour 
medical treatment. Interes tingly, in a study 
conducted in the UK National Health 
System, the cost of medical v. laparo-
scopic management showed that medical 
manage ment was only more cost-effective 
in patients with an initial β-hCG of 
<1 500 IU/L. This was due to the increased 
risk of complications, including emergency 
surgery, repeated admission and subsequent 
doses of methotrexate.[12]
Patient compliance with follow-up is a 
major obstacle in medical management, espe-
cially in lower-income areas. A retro spective 
analysis evaluating comp liance of inner-
city patients who received methotrexate at 
Bronx Lebanon Hospital Center in New 
York found that only 10% of patients were 
fully compliant with follow-up.[13] Simplified 
follow-up protocols with fewer visits have 
been suggested to improve compliance.[13]
There are many studies looking at 
treatment success of ectopic pregnancies 
with methotrexate, but none in an SA setting. 
This treatment modality is used at Tygerberg 
Hospital, Cape Town, but the objective 
outcomes are unknown. Our retrospective 
review set out to answer this question.
Objective
The objective of this study was to determine 
whether medical management of ectopic 
pregnancies with methotrexate in selected 
patients at Tygerberg Hospital was an 
effective and safe treatment option. The 
outcomes measured were the number of 
patients requiring surgical intervention 
despite methotrexate treatment, how many 
patients needed repeat doses of metho-
trexate, the average duration of follow-
up, time spent in hospital, complications 
associated with methotrexate use, and 
compliance of patients with follow-up.
The current protocol for medical manage-
ment is the single-dose methotrexate regi-
men. Recommendations for medical manage -
ment include a stable patient with a β-hCG of 
<4 000 IU/L, a mass of <40 mm in diameter, 
no fetal cardiac activity, and mini mal free 
fluid on ultrasound. β-hCG levels are 
monitored weekly until the value is <15 IU/L.
Methods
A 5-year retrospective audit was per-
formed. Ethical approval was obtained from 
the Health Research Ethics Committee of 
Stellen bosch University (ethics number: 
S12/08/229). All patients treated for 
ectopic pregnancies with metho trexate 
were in cluded. Exclusion criteria included 
cervical ectopic pregnancies, molar preg-
nancies, intrauterine pregnancies and 
pregnancies of unknown location. Patients 
were identified by obtaining a list from 
the pharmacy of all patients treated with 
methotrexate from 23 May 2008 to 23 May 
2013. Patient folders were systematically 
assessed, and information was extracted 
onto a data capture sheet which was then 
transferred to a MS Excel data sheet with 
data cleaning and checking.
Statistical analysis was performed using 
Statistica version 12 (StatSoft Inc., 2009). 
Descriptive statistics were used. Frequencies 
(counts and percentages), measures of 
location (mean and median) and spread 
(standard deviations (SDs) and percentiles) 
were used to describe distribution of the 
data; 95% confidence intervals (CI) are 
presented for measures of location, as well 
as for the relative frequencies (proportions). 
Student’s t-test, the Wilcoxon rank sum test 
and the exact χ2 test were used to assess 
differences in the study groups.
Results
A total of 181 patients were identified from 
pharmacy records; 124 met the inclusion 
criteria, and 42 were excluded because 
they had received methotrexate for another 
indication. Fifteen patient folders could not 
be found.
The mean age was 24.4 years (SD 5.47, 
range 17 - 44). Most were multigravidas 
(85%). Eighteen women (14%) had had 
one or more previous ectopic pregnancies. 
Twenty (16%) had documented previous 
sexually transmitted infections, with one 
woman having had surgery for acute 
Table 1. Presenting complaints
Complaint n (%)
Bleeding 37 (29.8)
Bleeding and pain 58 (46.8)
Pain 17 (13.7)
Ultrasound scan showed ectopic pregnancy 4 (3.2)
None (referred from primary care hospital for medical management, with no complaints) 8 (6.4)
Total 124 (100.0)
Surgery
n=18 (15%)
No surgery 
and β-hCG
<15 IU/L
n=55 (44%)
Other
n=51 (41%) Lost to follow-up
n=37 (30%)
β-hCG <50 IU/L
n=14
(11%)
Fig. 1. Outcomes after medical management with methotrexate. (β-hCG = beta-human 
chorionic gonadotrophin.)
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salpingo-oophoritis. Sixty-nine (48%) were cigarette smokers. 
None had an intrauterine contraceptive device in situ. Ten (8%) had 
documented fertility problems, and two (2%) had reversals of tubal 
ligations. Eleven women (9%) were HIV-positive and 50 (40%) HIV-
negative, but the majority (n=63, 51%) had unknown HIV status.
Over 75% of patients presented with either bleeding or a 
combination of bleeding and pain (Table 1).
If successful treatment with methotrexate was defined as a patient 
who was followed up to a β-hCG level of <15 IU/L, without requiring 
surgical intervention, the success rate was 44% (55/124) (Fig. 1).
Fourteen women were followed up to a β-hCG level of <50 IU/L, 
and checking the hospital database showed that they were not 
admitted to our hospital or any district hospital in our drainage 
area for further treatment. If success was redefined as follow-up to a 
β-hCG level of <50 IU/L, the success rate of methotrexate treatment 
would be 56% (59/124).
Repeat doses of methotrexate were required in 17 women (14%); 
nine were successfully treated and followed up to a β-hCG level of 
<15 IU/L, four did not complete follow-up, and four required surgery. 
One of the surgical patients received a third dose of methotrexate, 
and eventually had a laparoscopic salpingostomy for an unruptured 
ectopic pregnancy. The indication for surgery was a rising β-hCG level 
and not worsening clinical symptoms.
Eighteen women (15%) required surgi cal intervention. Four 
operations were per formed laparoscopically and 14 by open laparotomy. 
Twelve patients had clinical signs of possible rupture, and this was 
confirmed in 11 cases. Six operations were performed for increasing 
β-hCG levels, and none of these cases had ruptured. Potentially five 
patients could have received a second dose of methotrexate. Of the 
patients who required surgery, two had large amounts of free fluid at 
diagnosis, and four had β-hCG levels of >4 000 IU/L.
When comparing the successfully treated group with those who 
required surgical intervention, a significant difference in β-hCG 
levels was noted (mean 1 447 v. 2 701 IU/L; p=0.006) (Fig. 2).
Of the 12 patients who were treated with methotrexate with 
an initial β-hCG level of >4 000 IU/L, four were successfully 
treated, four required surgery and the remaining four did not 
complete follow-up.
The size of the ectopic mass at the time of diagnosis was 
significantly larger in the group who were successfully treated 
with methotrexate compared with those who required surgical 
intervention (mean 32.8 v. 23.7 mm; p=0.027). Seventeen patients 
had an initial ectopic mass size of >40 mm. Of these nine were 
successfully treated, two had surgery and six did not complete 
follow-up. Two women with a large amount of free fluid on 
ultrasound were given methotrexate, and both required surgery. 
Fourteen patients had a moderate amount of free fluid in the pouch 
of Douglas, of whom 11 (79%) were successfully treated and three 
(21%) required surgery. Twenty-three patients had minimal free 
fluid; 18 (78%) were treated successfully and five (22%) required 
surgery. Of the patients who had no free fluid, 12 (86%) were treated 
successfully and two (14%) required surgery. In no patient was fetal 
heart activity present on ultrasound.
The mean number of follow-up visits for those who were 
successfully treated was five (range 3 - 13). Of the group that did not 
complete follow-up, only five were lost after the first visit, and 28 
were followed up to four hospital visits or more. Ninety-two patients 
(74%) required admission to hospital. The high admission rate 
was mostly due to delay in diagnosis and obtaining methotrexate 
therapy.
In the successfully treated group, the β-hCG level on day 4 
dropped from the initial value in 45 of the 55 patients (mean drop 
53%). In the group that required surgery, only one of the 18 patients 
had a drop in β-hCG levels on day 4.
One patient had a major adverse outcome. She was readmitted 
3 days after receiving medical treatment with a ruptured ectopic 
that required emergency laparotomy and transfusion of 2 units 
of packed cells. There was one possible minor adverse effect. A 
patient presented one month after initial medical treatment with 
lower abdominal pain and was diagnosed with a urinary tract 
infection. She had elevation of the liver enzymes and marked 
renal impairment. She was admitted for one day and treated with 
antibiotics. This patient was HIV-negative. No further follow-up of 
her renal function was documented, and it is unclear whether there 
was any relationship to the initial methotrexate treatment.
Advice on the treatment, complications and follow-up was 
documented in 62% of the folders. Only 45 patients (35%) were 
discharged with contraception or contraceptive counselling; 19  were 
on injectable contraceptives, 11 on combined oral contraceptives 
and one on barrier methods. Twelve patients received counselling 
or referral to the family planning clinic. In five patients there was 
evidence of a pregnancy within the same year.
Discussion
In this study of the medical management of ectopic pregnancies 
with methotrexate, success was defined as follow-up to a β-hCG 
level of <15 IU/L. Our success rate was 44%, which is much lower 
than international reports of success rates of 88 - 93%.[10] These rates 
were achieved in prospective studies where loss to follow-up was not 
a contributory factor. If we included all patients who were followed 
up to a β-hCG level of <50 IU/L, the success rate would rise to 55%. 
The main reason for the low success rate in our study was poor 
follow-up, as 41% of the patients did not complete surveillance to 
β-hCG <15 IU/L. Other reasons included incorrect patient selection 
and incorrect application of the treatment protocol.
Seventeen (14%) of the total group required a repeat dose of 
methotrexate. This correlates with international rates, where about 
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Fig. 2. β-hCG levels of successful methotrexate management v. 
those requiring surgery. (β-hCG = beta-human chorionic gonado-
trophin.)
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20% of women require more than one treatment cycle.[10] In 52% of 
these cases, the treatment was successful with sufficient follow-up.
Eighteen patients (14%) required surgical intervention. This is 
higher than the international rates of 7 - 12%.[11] Of these patients, 
two had large amounts of free fluid on ultrasound and four initially 
had β-hCG level of >4 000 IU/L, so medical management was less 
likely to succeed. β-hCG levels were significantly higher in those 
with failed medical treatment. In five patients a second dose of 
methotrexate could have been given and surgery could potentially 
have been avoided. Implementing a standardised protocol, whereby 
decisions regarding treatment are consistent, is crucial.
No significant differences in the presence of free fluid on 
ultrasound or the size of the ectopic mass could be shown 
between the successfully treated patients and those who required 
surgery. Both patients with large amounts of free fluid on 
ultrasound who were treated with methotrexate required surgery. 
A large amount of free fluid is a contraindication to methotrexate 
therapy, and these patients should not have received medical 
management.
In our series, as was confirmed in 11 of 12 patients with pain 
requiring surgery, a presenting sign of pain after treatment with 
methotrexate was very suggestive of rupture. This is in contrast to 
the published literature, where most patients presenting with pain 
did not have a ruptured ectopic.[10] It was thought that the pain was 
due to tubal stretching in these cases.[10] It is possible that patients in 
our population group only present to hospital when their pain is very 
severe.
The size of the mass did not correlate with treatment failure; 
interestingly, in our series the mass was larger in the patients who 
were successfully treated with methotrexate. It has also been 
reported that size is not a good predictor of treatment success.[14] 
This is possibly because it is difficult to distinguish the surrounding 
haematoma from the actual ectopic mass.
The day 4 β-hCG level decreased in 42/55 of the successfully 
treated patients, and increased on day 4 in 12 of the 18 patients who 
required surgery. This correlates with the literature, where a decline 
in the day 4 β-hCG level has been associated with a success rate of 
88% for single-dose treatment.[15] If the level increases on day 4, the 
success rate is only 42%.[15]
Study limitations
Our study has limitations, as it is a retro spective review. There was 
a large loss to follow-up, and the patient notes often had missing 
information or were not complete. There may have been patients 
who were lost to follow-up and received surgical management at 
other private units. We checked the database for all the level 1 and 
2 hospitals in our drainage area, and none of the patients who were 
followed up to a β-hCG level of <50 IU/L had surgery performed 
in these units. These limitations highlight areas where we would be 
able to improve our management.
Conclusion
At present the medical management of ectopic pregnancies at 
our institution is suboptimal. We need to implement a protocol 
that will enable doctors to correctly select patients who not only 
meet the criteria for treatment, but are also able and willing to be 
followed up according to the recommended regimen. Staff training 
is essential, and doctors and nurses providing this treatment should 
have sound knowledge of the selection criteria and the follow-up 
regimen. Patients should be thoroughly counselled. Baseline renal 
and liver function tests are probably not necessary for single-dose 
treatment with methotrexate if a good history is taken and clinical 
examination done. This is important, as it would minimise cost. 
Access to ultrasound and methotrexate should be improved to avoid 
unnecessary admission to hospital. There are risks associated with 
the medical management of ectopic pregnancies. Patients must be 
informed of these risks, and the benefits of this treatment option 
and the other treatment options available.
Medical treatment does decrease the number of patients needing 
surgery, which is very helpful in hospitals with over burdened 
theatre lists. Medical treatment is a safe option if correct advice, 
documentation and follow-up are provided. Currently this is not the 
case at our institution.
We recommend that a follow-up pro gramme is developed where 
patients are contacted if they do not attend. Patients should be 
advised that they may need to return for follow-up on average 
five times, with the possibility of up to ten visits. They must be 
informed that a second dose of methotrexate is required in up 
to 20% of cases, and that there may still be a need for surgery. 
They should be advised to delay conception for at least 12 
weeks after treatment, they should be tested for HIV infection, 
and contraceptive counselling should be offered. Detailed 
documentation is essential.
We intend to design a patient-kept card providing information 
about medical treatment with methotrexate, the risks and 
benefits, warning signs, contact telephone numbers, follow-
up dates and β-hCG values. It will also include advice about 
contraception. The card will enable patients to be followed up 
at their primary care hospital, which would be less costly and 
time-consuming for them. This should improve compliance with 
follow-up and the safety of medical treatment with methotrexate 
for ectopic pregnancies.
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